NES and glioma: In other PDGF-driven glioma mouse models, the incidence of tumors was 33% at 3 months when targeting oligodendroglial progenitors using the CNP promoter (Ctv-a mouse, [19]), 50% at 3 months when targeting neural/glial stem cells with Nestin promoter (Ntv-a mouse, [37]) and 16% at 3 months when targeting astrocytes using GFAP promoter (Gtv-a mouse, [37]).